We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Nanopore Technologies Plc | LSE:ONT | London | Ordinary Share | GB00BP6S8Z30 | ORD GBP0.0001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.90 | -2.91% | 130.00 | 3,410,174 | 16:35:24 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 130.60 | 130.90 | 134.10 | 129.20 | 134.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 169.67M | -154.51M | -0.1768 | -7.40 | 1.17B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:47:03 | O | 150,000 | 130.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/7/2024 | 20:09 | ALNC |  EARNINGS AND TRADING: Alphaware new bookings rise; Marston's Euro lift |
| 24/7/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Half Year Trading Update |
| 23/7/2024 | 09:55 | ALNC | Oxford Nanopore expands collaboration with LA-based Plasmidsaurus |
| 23/7/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Plasmidsaurus collaboration and contract.. |
| 16/7/2024 | 07:00 | UK RNS | Oxford Nanopore Technologies plc Appointment of corporate broker |
| 11/7/2024 | 16:30 | UK RNS | Oxford Nanopore Technologies plc Share Incentive Plan - Director/PDMR.. |
| 03/7/2024 | 17:30 | UK RNS | Oxford Nanopore Technologies plc Founder LTIP - Director/PDMR Notification |
| 01/7/2024 | 16:30 | UK RNS | Oxford Nanopore Technologies plc Total Voting Rights |
| 28/6/2024 | 16:30 | UK RNS | Oxford Nanopore Technologies plc Founder LTIP - Director/PDMR Notification |
| 21/6/2024 | 17:33 | UK RNS | Oxford Nanopore Technologies plc Issue of Equity and Total Voting Rights |
Oxford Nanopore Technolo... (ONT) Share Charts1 Year Oxford Nanopore Technolo... Chart |
|
1 Month Oxford Nanopore Technolo... Chart |
Intraday Oxford Nanopore Technolo... Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/7/2024 | 15:03 | OXFORD NANOPORE | 1,504 |
| 10/5/2004 | 09:41 | Ј8m boost for Online Travel | 473 |
| 29/1/2004 | 21:48 | Online Travel - Superb chart and fundamentals | 3 |
| 19/12/2003 | 17:11 | ONT - 4 new contracts worth Ј7million | 310 |
| 15/10/2003 | 03:30 | Online Travel Corporation | 962 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 16:15:00 | 130.00 | 257,488 | 334,734.40 | O |
| 2024-07-26 15:47:06 | 130.33 | 19,012 | 24,777.77 | O |
| 2024-07-26 15:42:19 | 133.17 | 15,000 | 19,976.00 | O |
| 2024-07-26 15:42:19 | 133.17 | 15,000 | 19,976.00 | O |
| 2024-07-26 15:42:19 | 131.61 | 107,488 | 141,470.20 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Oxford Nanopore Technolo... Daily Update Oxford Nanopore Technologies Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker ONT. The last closing price for Oxford Nanopore Technolo... was 133.90p.Oxford Nanopore Technolo... currently has 873,871,414 shares in issue. The market capitalisation of Oxford Nanopore Technolo... is £1,143,023,810. Oxford Nanopore Technolo... has a price to earnings ratio (PE ratio) of -7.40. This morning ONT shares opened at 134p |
Posted at 24/7/2024 07:07 by seball No change in guidance and continued confidence to meet 2024 outlook. This will be taken as good news and share price will continue to rise over coming months. This is a sitting duck for a takeover once anti takeover shares expire in October.Good luck all |
Posted at 24/7/2024 07:04 by bamboo2 24 July 2024Oxford Nanopore Technologies plc Half Year Trading Update · Trading in-line with both revenue and gross margin guidance in the face of challenging end-markets · Building commercial momentum heading into the second half reinforces confidence; full year 2024 and medium-term guidance reaffirmed Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of molecular sensing technology based on nanopores, today provides a trading update for the six months ended 30 June 2024 ahead of results, which will be published on 3 September 2024. The Group expects to report Life Sciences Research Tools (LSRT) revenue for the six months ended 30 June 2024 of approximately £84 million (H1 2023: £86.0 million), broadly flat year-on-year at constant currency; marginally down (2%) on a reported basis, including foreign exchange headwinds. Underlying[1] LSRT revenue, grew by 12.4% on a constant currency basis year-on-year. Growth for the first half of 2024 is in-line with expected 2024 phasing. Underlying growth has been strongest across the PromethION franchise[2], across all product lines. Underlying growth was delivered across each region, and it was strongest across EMEAI and APAC, with commercial momentum building for the second half, supported by new product launches, a number of new and expanded contracts, and a step up in sales team productivity in the second quarter. Gross margin for the first half is expected to show year-on-year improvement, despite foreign exchange headwinds, and remains on track to meet the Group's full year 2024 guidance. Outlook Full year 2024 guidance remains unchanged: - LSRT revenue growth is expected to be between 6 and 15% on a constant currency basis and underlying revenue growth is expected to be between 20 and 30% on a constant currency basis. The Group continues to expect FY 2024 revenue to be second half weighted, with an approximate 45:55 split. - Gross margin is expected to be approximately 57%. All medium-term (FY 2027) guidance is unchanged. Gordon Sanghera, Chief Executive Officer, commented: "Our first half performance is in-line with our expectations. We delivered robust underlying revenue growth, despite a challenging macroeconomic backdrop. "We enter the second half in a strong position; new contract wins coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in our full year 2024 outlook. In addition, the launch of new products from our regulated pipeline, including GridION Q-Line and ElysION, our sample-to-answer automated sequencing solution, will drive adoption in new clinical and applied markets in the near and medium-term." |
Posted at 23/7/2024 08:22 by bamboo2 RNS NON 23/7/2024Oxford Nanopore Technologies plc Oxford Nanopore and Plasmidsaurus announce collaboration and multi-year, multi-million dollar contract expansion Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and Plasmidsaurus, the LA-based company that introduced overnight whole-plasmid sequencing, today announce a new strategic collaboration to advance plasmid sequencing beyond legacy methods, and an expanded multi-year, multi-million dollar global contract. Plasmidsaurus' whole-plasmid sequencing is used by researchers and industry professionals around the world for a broad spectrum of applications, from basic research to industrial applications, gene therapy, vaccine development, genetic engineering and more. Its sequencing capabilities are based on Oxford Nanopore's real-time, long-read sequencing technology, which has enabled Plasmidsaurus to set new standards for quality and speed, delivering overnight results and richer datasets that unlock more accurate, comprehensive, and reliable insights. The extension of the existing contract will see the collaboration continue to take share of a fast-growing estimated $1.5B market opportunity in synthetic biology as nanopore-based sequencing continues to displace traditional methods, such as Sanger, for plasmid sequencing. Founded in 2021, Plasmidsaurus has since opened nine labs in three countries and is expanding its global network of 660 dropboxes and labs in key biotech hubs, including new locations in the US, Europe, and Asia. Plasmidsaurus became an Oxford Nanopore customer in 2021. As strategic collaborators going forward, Oxford Nanopore and Plasmidsaurus also intend to co-develop new technologies, reagents, and applications beyond plasmid sequencing, including microbial and gene therapy use cases, to best meet evolving market needs, providing further market share opportunities. Gordon Sanghera, CEO of Oxford Nanopore commented: "By collaborating with Plasmidsaurus, we are advancing the fields of synthetic biology and biotechnology through the unique capabilities of nanopore technology that are not possible with legacy methods. Our joint efforts will drive significant market growth and deliver best-in-class sequencing services to a global audience." |
Posted at 26/6/2024 08:07 by seball Almost half of Mcap is Cash. This drop is over done Price target £1.60 and some even higher.On Monday, Barclays (LON:BARC) adjusted its price target on shares of Oxford Nanopore Technologies (ONT:LN) (OTC: ONTTF), reducing it to GBP1.60 from GBP1.85, while maintaining an Overweight rating on the stock. The revision reflects the firm's outlook for the company in light of recent market conditions and operational strategies. The company faced challenges in the last two quarters, which have been a period of assessment for many firms in the sector. Despite these hurdles, Barclays anticipates some sequential improvements in Oxford Nanopore's end markets. Oxford Nanopore's revenue composition is expected to be more heavily weighted towards the second half of the year. This projection is supported by several factors including new product launches, increased utilization of the company's offerings, and the timing of larger projects that are in the pipeline. The firm highlights Oxford Nanopore's capital expenditure-light business model as a distinctive advantage. This approach could potentially set the company apart from competitors in the biotechnology and genomics industry, which often require significant upfront investments. In summary, while the price target has been lowered, the Overweight rating suggests that Barclays continues to see Oxford Nanopore as a favorable investment, with positive developments anticipated in the latter half of the year. |
Posted at 22/4/2024 11:58 by brucie5 "Non pasaran!"Well maybe. Small buys look like being soaked up. Anyone with level 2 access care to share what they see this morning? My conjecture continues to be that this is capitulation. I'm surprised that anyone left in would be still trying to sell. As yet nothing to send the share the other way, except some correction of the oversold situation on the chart. The 50sma, with which the share price not infrequently makes contact on the way down is at 1.30p. So best guess is that we could see a 25% correction the other way without even touching the current trend. In the medium term I continue to look for the recapturing of the £1 level before we see a credible base begin to build. All on the tea leaves, obviously, so NAI. |
Posted at 13/4/2024 12:27 by 74tom Last few thoughts from me for now;1. The decline has been driven by low volume, with the average daily value of shares traded in 2024 sitting at £2m (2021 was £12.7m, 2022 was £5.4m and 2023 was £3m). A bottom normally forms when volume is high, so there is no capitulation from large shareholders, it's just a sustained downward pressure. 2. The heavy shorting of US listed arch rival Pacbio is undoubtedly influencing ONT's share price. From my research there appears to be a significant chance of them becoming insolvent, with their market cap of $844m exceeded by $892m of Convertible note debt, and cash of $631m declining by ~$80m per quarter. Cumulative shares held short were 49m at 28th March, which is ~18% of it's float, up from 10% this time last year. Conversely to ONT, PACB has sold off on significantly higher than average volume, as you can see from @Bamboo2,s chart above. It will be very interesting to see how things play out this year, if PACB are commercially impaired then it can only be a good thing for ONT in my opinion. |
Posted at 23/3/2024 12:01 by bamboo2 Price action is far from ideal.This is a weak sector at present. Hopefully it should change at some point, as massive expansion of sequencing around the world is forecast. The UK market is discounting many growth and tech stocks, and analysts have taken against ONT management and their attempts to be realistic in the face of unexpected problems, such as the ban on export of devices containing NVDA chips to China. On the positive side, ONT has almost completed the planned increases of staff in technical, manufacturing and sales functions. Naturally, this should increase turnover. Accuracy continues to improve and customer sentiment is at all time highs. The new ASIC should get an airing in May 2024. Management have so far made no attempt to extend the life of LAT shares that expire in June 2024, which means takeover potential could lift the valuation. There are a large number of organisations around the world that could currently buy the whole company for pocket money. I find ONT one of the most exciting companies in the UK, and despite a losing position at present will continue to hold for the long term. |
Posted at 22/3/2024 16:53 by minsky x = ONT share price;while x > 0 { bamboo2 posts article about ONT success; x = x-2; } |
Posted at 04/12/2023 19:47 by bamboo2 Some detective work on the remainder of the Woodford holding [formerly the Woodford Patient Capital Trust holding] which is now managed by Schroders under the ticker INOV.Nortrust Nominees Limited A/C WIZ02(7) Prior to admission 25,927,100 3.65% Post admission 23,334,390 2.94% Beneficial interest in these Ordinary Shares was held by Schroder UK Public Private Trust plc under the ticker SUPP, now known as INOV. Day/mth/yr Holding value ONT share price quantity held 31/12/2022 £56,529,000 2.466 = 22,923,357 30/06/2023 £44,000,000 2.132 = 20,599,250 30/09/2023 £42,100,000 2.056 = 19,990,272 Therefore, at eod on 30/9/2023 INOV held 2.33% They are committed to 'rebalancing' their portfolio, so I expect the selling to continue. |
Posted at 19/10/2023 07:56 by bamboo2 BioMérieux makes strategic investment in Oxford Nanopore19 October 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION Oxford, UK and Marcy-l'Étoile, France, 19 October 2023. Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics ("IVD") today announce that bioMérieux is making an immediate GBP70M investment in Oxford Nanopore. In addition, bioMérieux expects to make further market purchases of Oxford Nanopore's shares from time to time, up to a further 3.5% of Oxford Nanopore's shares, subject to availability and price. The investment strengthens the relationship between the two companies, further aligning with Oxford Nanopore's increasing focus on clinical markets through a partnership announced in April this year. This investment will support development for products in Oxford Nanopore's portfolio to serve IVD markets in conjunction with bioMérieux's commitment to advancing global public health. Through this partnership and this investment, the two companies intend to leverage Oxford Nanopore's ground-breaking nanopore-based IVD solution and bioMérieux's IVD expertise in R&D, Regulatory, Medical and Market Access. As part of the transaction, the two companies will establish an IVD Advisory Board to advance nanopore technology into routine clinical use. Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features and advances in single-nucleotide sequencing accuracy of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples. Together, the companies are driving to meet a significant unmet need in the clinical and diagnostic markets- an opportunity where nanopore sequencing is uniquely suited to deliver impact where information-rich, rapid, accessible, and affordable sequencing are critical. Oxford Nanopore reconfirms its guidance to be adjusted EBITDA breakeven by the end of 2026. Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented: "With bioMérieux's strategic investment and our shared commitment to innovation, we are poised to accelerate the development of nanopore-based IVD solutions. This investment will enable us to deliver rapid, accessible, and affordable clinical tools more quickly to address unmet needs and improve healthcare worldwide." Pierre Boulud, bioMérieux CEO, commented: "This investment will reinforce our existing partnership with Oxford Nanopore and provide more resources for the development of innovative IVD solutions. Drawing on our six decades of expertise in the in vitro diagnostic space, we consider that the new generation of sequencing technology developed by Oxford Nanopore holds promise to answer future diagnostic needs and will further improve patient care, in particular against the ever-growing infectious diseases threat." Transaction structure -- bioMérieux has agreed to subscribe for 29,025,326 ordinary shares (which equates to 3.5% of Oxford Nanopore's voting rights as at 13 October 2023) in Oxford Nanopore at a subscription price of 238.08p per share (the "Subscription"), conditional only upon Admission (as defined below) occurring. This represents a total investment of nearly GBP70 million. -- Applications will be made to the Financial Conduct Authority and the London Stock Exchange for the shares issued pursuant to the Subscription to be admitted to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange ("Admission"). -- Admission is expected to occur on Monday 23 October 2023. -- The Subscription price of 238.08p per share is equal to the 6-month volume weighted average price as at 13 October 2023. As part of the Subscription, subject to certain customary exceptions, bioMérieux undertakes to: -- For a period of 5 years, not acquire or agree to acquire any interests in Oxford Nanopore's shares which would result in it and its affiliates having an interest exceeding 9.9% of the issued share capital of Oxford Nanopore (provided that this restriction shall be suspended for so long as Oxford Nanopore is in an offer period (included in the Definitions of the City Code on Takeovers and Mergers (the "Code")), and in the case of an offer period which is commenced by an announcement under Rule 2.4 of the Code, for a one month period after the cessation of such offer period); -- not dispose of any shares in Oxford Nanopore for 12 months, subject to certain limited exceptions; and -- comply with certain orderly marketing obligations for a period of four years after expiry of the 12-months lock-up period, subject to certain limited exceptions. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
